InsiderTrades.com logo
This company will win the AI race
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.
Patrick F. Smith net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Patrick Smith Biography and Net Worth

Insider of Certara
Dr. Patrick F. Smith is President of Integrated Drug Development at Certara, where he leads a global team of drug development scientists that creates value for clients across the entire life cycle and ultimately accelerates patient access to medicines.  With more than 20 years of drug development experience, Patrick has worked across all phases of drug development with deep expertise in infectious diseases, oncology, and inflammation as well as novel early development program design and applying modeling and simulation to solve critical development problems.

Previously, Patrick was co-founder of d3 Medicine (acquired by Certara in 2016), helping to build a healthcare company that specialized in providing strategic support for complex development programs.  Prior to d3 Medicine, Patrick was U.S. Clinical Pharmacology Lead at Roche for more than 5 years, where he worked in various roles of increasing responsibility in clinical pharmacology and translational medicine.  He has served as an Associate Professor at the University at Buffalo School of Pharmacy and Roswell Park Cancer Institute in Buffalo, NY.  Patrick has published more than 125 peer-reviewed articles in journals, including the New England Journal of Medicine and Lancet.  He holds a PharmD from the University of California, San Francisco and completed his clinical residency at Duke University Medical Center.

What is Patrick F. Smith's net worth?

The estimated net worth of Patrick F. Smith is at least $478,369.05 as of October 7th, 2024. Dr. Smith owns 50,091 shares of Certara stock worth more than $478,369 as of November 20th. This net worth approximation does not reflect any other assets that Dr. Smith may own. Additionally, Dr. Smith receives an annual salary of $582,020.00 as Insider at Certara. Learn More about Patrick F. Smith's net worth.

How old is Patrick F. Smith?

Dr. Smith is currently 53 years old. There are 4 older executives and no younger executives at Certara. The oldest executive at Certara is Mr. Leif E. Pedersen, President & Chief Commercial Officer, who is 59 years old. Learn More on Patrick F. Smith's age.

What is Patrick F. Smith's salary?

As the Insider of Certara, Inc., Dr. Smith earns $582,020.00 per year. There are 3 executives that earn more than Dr. Smith. The highest earning executive at Certara is Dr. William F. Feehery Ph.D., CEO & Director, who commands a salary of $1,320,000.00 per year. Learn More on Patrick F. Smith's salary.

How do I contact Patrick F. Smith?

The corporate mailing address for Dr. Smith and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on Patrick F. Smith's contact information.

Has Patrick F. Smith been buying or selling shares of Certara?

Over the course of the past ninety days, Patrick F. Smith has sold $59,661.27 in Certara stock. Most recently, Patrick F. Smith sold 5,409 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a transaction totalling $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares of the company's stock, valued at $552,503.73. Learn More on Patrick F. Smith's trading history.

Who are Certara's active insiders?

Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.

Are insiders buying or selling shares of Certara?

During the last year, insiders at the sold shares 6 times. They sold a total of 86,060 shares worth more than $1,151,075.18. The most recent insider tranaction occured on October, 7th when insider Patrick F Smith sold 5,409 shares worth more than $59,661.27. Insiders at Certara own 2.4% of the company. Learn More about insider trades at Certara.

Information on this page was last updated on 10/7/2024.

Patrick F. Smith Insider Trading History at Certara

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2024Sell5,409$11.03$59,661.2750,091View SEC Filing Icon  
4/2/2024Sell14,427$16.85$243,094.9550,091View SEC Filing Icon  
6/5/2023Sell19,104$21.55$411,691.2059,975View SEC Filing Icon  
8/16/2022Sell10,000$17.71$177,100.0078,490View SEC Filing Icon  
6/8/2022Sell10,000$19.16$191,600.0088,490View SEC Filing Icon  
4/4/2022Sell3,352$22.29$74,716.0898,490View SEC Filing Icon  
See Full Table

Patrick F. Smith Buying and Selling Activity at Certara

This chart shows Patrick F Smith's buying and selling at Certara by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Certara Company Overview

Certara logo
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $9.55
Low: $9.55
High: $9.94

50 Day Range

MA: $10.82
Low: $9.55
High: $11.75

2 Week Range

Now: $9.55
Low: $9.55
High: $19.87

Volume

661,002 shs

Average Volume

792,982 shs

Market Capitalization

$1.54 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51
This company will win the AI race
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.